USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Indian Diabetes Market
18-Mar-2013
South Asia, Middle East & North Africa
Market Research
P674-01-00-00-00
LS00137-SA-MR_16978
$4,950.00
Special Price $3,712.50 save 25 %
This research service studies the Indian Diabetes market. It provides the number of Type 1 and Type 2 diabetic patients in India across different age groups and forecasts these numbers up to 2030. It provides a detailed analysis of the two major segments of the market, the insulin market segment and the anti-diabetic medications segment, which includes oral anti-diabetics as well as injectable ones. Drivers and Restraints faced by the participants in this market have been analysed. Based on these, a quantitative analysis and revenue forecast from 2011 up to 2017 has been provided for the total market as well as the two segments: Insulin and Anti-diabetic medications. Finally, strategic recommendations have also been provided.
Executive Summary
Executive Summary (continued)
Executive Summary—Market Engineering Measurements
Executive Summary—Market Engineering Measurements (continued)
Executive Summary—CEO’s Perspective
Market Overview—Definitions
Market Overview—Definitions (continued)
Market Overview—Definitions (continued)
Market Overview—Definitions (continued)
Diabetes Overview—Global
Worldwide Diabetes Overview
Market Overview—Key Questions This Study Will Answer
Market Overview—Segmentation
Market Overview—Patient Share Forecast by Treatment Type
Market Overview—Patient Share Forecast by Treatment Type (continued)
Total Diabetes Market: Key Treatment Challenges in India (2011)
Distribution Channels
Southeast Asia Diabetes Overview
Southeast Asia Diabetes Overview (continued)
Drivers and Restraints
Drivers Explained
Drivers Explained (continued)
Drivers Explained (continued)
Drivers Explained (continued)
Drivers Explained (continued)
Restraints Explained
Restraints Explained (continued)
Restraints Explained (continued)
Restraints Explained (continued)
Restraints Explained (continued)
Market Engineering Measurements
Forecast Assumptions
Total Diabetes Market—Revenue Forecast
Revenue Forecast Discussion
Total Diabetes Market—Per cent Revenue Forecast by Segment
Per cent Revenue Forecast by Segment Discussion
Diabetes Population Overview—India
Diabetes Population Overview—India (continued)
Diabetes Population Overview—India (continued)
Patient Share Forecasts
Market Potential
Companies by Product Segment
Competitive Analysis—Market Share
Market Share Analysis
Competitive Environment
Insulin Segment Breakdown
Insulin Segment—Market Engineering Measurements
Insulin Segment—Revenue Forecast
Insulin Segment—Revenue Forecast Discussion
Competitive Analysis—Segment Share
Competitive Analysis—Segment Share
Competitive Environment
Insulin Versus Insulin Analogues
Insulin Versus Insulin Analogues (continued)
R&D Pipeline
R&D Pipeline (continued)
Intermediate-Acting Insulin—Market Engineering Measurements
Intermediate-Acting Insulin—Competitive Analysis
Fast-Acting Insulin—Market Engineering Measurements
Fast-Acting Insulin—Competitive Analysis
Long-Acting Insulin—Market Engineering Measurements
Long-Acting Insulin—Competitive Analysis
Pre-Mixed Insulin—Market Engineering Measurements
Pre-Mixed Insulin—Competitive Analysis
Animal Insulin—Market Engineering Measurements
Animal Insulin—Competitive Analysis
Insulin Delivery
Insulin Delivery (continued)
Insulin Delivery (continued)
Anti-Diabetics Medications Segment Breakdown
Anti-Diabetes Medications Segment—Market Engineering Measurements
Anti-Diabetes Medications Segment—Revenue Forecast
Revenue Forecast Discussion
Competitive Analysis—Segment Share
Competitive Analysis—Segment Share (continued)
Competitive Environment
Biguanides (metformin)
Biguanides (metformin)—Market Engineering Measurements
Biguanides (metformin)
Sulfonylureas
Glimepiride—Market Engineering Measurements
Glimepiride
Glibenclamide—Market Engineering Measurements
Glibenclamide
Gliclazide—Market Engineering Measurements
Gliclazide
Glipizide—Market Engineering Measurements
Glipizide
Alpha-Glucosidase Inhibitors
Voglibose—Market Engineering Measurements
Voglibose—Product Portfolio
Acarbose—Market Engineering Measurements
Acarbose—Product Portfolio
Thiazolidinediones
Rosiglitazone Banned in India
Pioglitazone—Market Engineering Measurements
Pioglitazone—Product Portfolio
Meglitinides
Repaglinide—Market Engineering Measurements
Repaglinide—Product Portfolio
Nateglinide—Market Engineering Measurements
Nateglinide—Product Portfolio
DPP-IV Inhibitors
Sitagliptin—Market Engineering Measurements
Sitagliptin—Product Portfolio
Vildagliptin—Market Engineering Measurements
Vildagliptin—Product Portfolio
Saxagliptin—Market Engineering Measurements
Saxagliptin—Product Portfolio
Linagliptin—Market Engineering Measurements
Linagliptin—Product Portfolio
Exenatide—Market Engineering Measurements
Exenatide—Product Portfolio
Liraglutide—Market Engineering Measurements
Liraglutide—Product Portfolio
Fixed-Dose Combination
Fixed-Dose Combination (continued)
Fixed-Dose Combination (continued)
Fixed-Dose Combination (continued)
Fixed-Dose Combination (continued)
Glimepiride + metformin
Glimepiride + metformin—Market Engineering Measurements
Glimepiride + metformin—Product Portfolio
Sitagliptin + metformin
Sitagliptin + metformin—Market Engineering Measurements
Sitagliptin + metformin—Product Portfolio
Glipizide + metformin
Glipizide + metformin—Market Engineering Measurements
Glipizide + metformin—Product Portfolio
Gliclazide + metformin
Gliclazide + metformin—Market Engineering Measurements
Gliclazide + metformin—Product Portfolio
Glibenclamide + metformin
Glibenclamide + metformin—Market Engineering Measurements
Glibenclamide + metformin—Product Portfolio
Vildagliptin + metformin
Vildagliptin + metformin—Market Engineering Measurements
Vildagliptin + metformin—Product Portfolio
Pioglitazone + metformin
Pioglitazone + Metformin—Market Engineering Measurements
Pioglitazone + metformin—Product Portfolio
Pioglitazone + Glimepiride
Pioglitazone + Glimepiride—Market Engineering Measurements
Pioglitazone + Glimepride—Product Portfolio
Metformin + Voglibose
Metformin + Voglibose—Market Engineering Measurements
Metformin + Voglibose—Product Portfolio
Pioglitazone + metformin + Glimepiride
Pioglitazone + metformin + Glimepiride—Market Engineering Measurements
Pioglitazone + metformin + Glimepiride—Product Portfolio
Future Trends in Diabetes Management
Future Trends in Diabetes Management (continued)
Novo Nordisk
Sanofi Aventis
Eli Lilly
Biocon
Novartis
USV
Lupin
MSD (Merck Sharp & Dohme)
Intas Pharma
Dr Reddy’s
Strategic Recommendations
Strategic Recommendations (continued)
Strategic Recommendations (continued)
Strategic Recommendations (continued)
Strategic Recommendations (continued)
The Last Word—Three Big Predictions
The Last Word—Discussion
Legal Disclaimer
Market Engineering Methodology
Learn More—Next Steps
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Lightbox Content | World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019 |
| WIP Number | P674-01-00-00-00 |
| Is Prebook | No |